In clinical trials3,4,5Evidence: Large human trialsInfections

Aviptadil3

Also called Zyesami3

Key takeaway

Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP), a 28-amino-acid human peptide, recorded in FDA’s substance registry.3 In TESICO, a randomized, placebo-controlled trial of 461 adults in intensive care or on breathing support for COVID-19 respiratory failure, aviptadil did not improve recovery or survival at 90 days.4 No FDA approval is reported in the sources reviewed here. Aviptadil does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.3,5,7

Aviptadil at a glance

What it isA synthetic 28-amino-acid peptide with the sequence of human vasoactive intestinal peptide, recorded as aviptadil and, in its acetate form, under the name Zyesami in FDA’s substance registry.3
FDA statusNo FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list aviptadil.3,5
Human evidenceOne large randomized, placebo-controlled trial (TESICO) in 461 adults with COVID-19 respiratory failure, which found no benefit, published in 2023.4
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is aviptadil?

Aviptadil is a synthetic peptide of 28 amino acids matching human vasoactive intestinal peptide. FDA’s substance registry records it as aviptadil and VIP, and its acetate salt under the name Zyesami.3

How is aviptadil thought to work?

The TESICO investigators describe aviptadil as a lung-protective neuropeptide and tested whether it could improve recovery from COVID-19 respiratory failure.4

What do human studies show?

TESICO randomized adults hospitalized with COVID-19 respiratory failure at 28 U.S. sites; 461 received at least part of their assigned aviptadil or placebo, and 94% were in intensive care at the start.4

At day 90, aviptadil did not improve the main recovery outcome. Deaths up to day 90 were 38% with aviptadil and 36% with placebo, and the trial was stopped early for futility.4

ClinicalTrials.gov lists TESICO (NCT04843761) and a second Phase 3 COVID-19 trial (NCT06729606) as completed in their October 2025 records.1,2

What the evidence base contains

  • Large randomized human trial TESICO (NCT04843761): a randomized, placebo-controlled trial of aviptadil in 461 adults with COVID-19 acute hypoxaemic respiratory failure at 28 U.S. sites, stopped early for futility (2023).4

Evidence-strength label: Large randomized human trials. How this label is assigned

Is aviptadil FDA-approved?

None of the sources reviewed here reports an approval of aviptadil by FDA.3,5

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list aviptadil.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Aviptadil is not among them.6,7

Timeline

  1. TESICO’s independent safety board recommends stopping the aviptadil comparison for futility.4
  2. The TESICO results are published.4
  3. FDA’s compounding safety-risk page is last updated; it does not list aviptadil.5

What is still unknown?

Whether it helps in any other condition: the large trial cited here studied only COVID-19 respiratory failure and found no benefit.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Aviptadil: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Aviptadil are a bounded selection, not every registration or paper about Aviptadil. For the years before Aviptadil was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Aviptadil as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Aviptadil in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not FDA-approved; studied in clinical trials. In a randomized, placebo-controlled trial of 461 adults with COVID-19 respiratory failure, aviptadil did not improve recovery or survival. Aviptadil is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Aviptadil?

Not FDA-approved; studied in clinical trials. In a randomized, placebo-controlled trial of 461 adults with COVID-19 respiratory failure, aviptadil did not improve recovery or survival. Aviptadil is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
2
Source years
5
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 16, 2026

    Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage?↗Source date September 25, 2026
  2. Literature metadata · added November 16, 2026

    Molecular Interactions of Zyesami with the SARS-CoV-2 nsp10/nsp16 Protein Complex.↗Source date January 27, 2026
  3. Literature metadata · added November 16, 2026

    Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.↗Source date December 12, 2025

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Aviptadil?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

9Selected dated records
14Connected citations
5Populated source years2019–2026
2/4Record lanes present

Registered human studies

Trial composition

2 of 2 selected trial records include at least one phase value; 2 of 2 include a status value in the retained structured contract.

PhasesPhase 3 2
Status at observationCompleted 2

PubMed bibliography

Publication composition

7 of 7 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 6Review 3Research Support, Non-U.S. Gov't 2Comparative Study 1Editorial 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
9

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 9 dated records

Research hub

Explore the Aviptadil evidence record

Open all 9 records →
9Dated records
2Evidence types
9Cited public sources
5Source years

Change ledger

Recently changed for Aviptadil

Open all 9 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT04843761

PeptideScanner retained ClinicalTrials.gov record NCT04843761 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was aviptadil.

PeptideScanner change date
November 16, 2026
Cited source date
October 24, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06729606

PeptideScanner retained ClinicalTrials.gov record NCT06729606 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-09, and PeptideScanner's reviewed identity mapping was aviptadil.

PeptideScanner change date
November 16, 2026
Cited source date
October 9, 2025
Evidence lane
Clinical trials
Record added

Aviptadil (Senatek).

PubMed lists PMID 11566015 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Review, with publication-date metadata of 2001-04 (month precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 16, 2026
Cited source date
January 1, 2019
Evidence lane
Literature metadata

Official-source collections

Source records for Aviptadil

Open the full research atlas →
PubMed7

7 with attributed title, venue, publication-date, and type metadata.

  1. Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage?Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025 11 18
  2. Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025 11 18
  3. Peptiligase, an enzyme for efficient chemo-enzymatic synthesis of aviptadil.International journal of biological macromolecules · 2023 09 27
Explore all selected literature →

Evidence types

Coverage by source year

Selected records span January 1, 2019 to September 25, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration3,5
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 9

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    Aviptadil in Acute Respiratory Distress Syndrome-Promise or Mirage?↗

    PubMed lists PMID 41368453 in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine as Editorial, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    Molecular Interactions of Zyesami with the SARS-CoV-2 nsp10/nsp16 Protein Complex.↗

    PubMed lists PMID 35975856 in Combinatorial chemistry & high throughput screening as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023 (year precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Literature metadata

    Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.↗

    PubMed lists PMID 41368449 in Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine as Journal Article, Review, with publication-date metadata of 2025-11-18 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04843761↗

    PeptideScanner retained ClinicalTrials.gov record NCT04843761 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-24, and PeptideScanner's reviewed identity mapping was aviptadil.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT06729606↗

    PeptideScanner retained ClinicalTrials.gov record NCT06729606 at 2026-11-16T01:46:32.736Z. Its registry update date was 2025-10-09, and PeptideScanner's reviewed identity mapping was aviptadil.↗

  6. Literature metadata

    Peptiligase, an enzyme for efficient chemo-enzymatic synthesis of aviptadil.↗

    PubMed lists PMID 37774815 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2023-09-27 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    Anticipated pharmacological role of Aviptadil on COVID-19.↗

    PubMed lists PMID 34846667 in Environmental science and pollution research international as Journal Article, Review, with publication-date metadata of 2021-11-30 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Aviptadil (Senatek).↗

    PubMed lists PMID 11566015 in Current opinion in investigational drugs (London, England : 2000) as Journal Article, Review, with publication-date metadata of 2001-04 (month precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Literature metadata

    Analytics of the therapeutic peptide aviptadil by sheathless CE-MS and comparison with nanoRP-HPLC-MS.↗

    PubMed lists PMID 24176753 in Journal of pharmaceutical and biomedical analysis as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-10-05 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT04843761 · retained source version 2025-10-24:498f0fee5198e31733ee7b2afda3addf993427b30558424653de2ccc3a35b1d9 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT06729606 · retained source version 2025-10-09:339ec06a5af5887227465781f32e0b6ebc00bd09fc8552fb166e1f35a6cc4cb2 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    Aviptadil substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (2023) · PMID 37348524 ↗

    The Lancet Respiratory Medicine · Official source · Source checked November 15, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026